Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the progressive decline in memory, language, cognition and motor functions. The neuropathological hallmarks of AD are the accumulation of extracellular amyloid plaques containing the amyloid beta peptide (A ) and intraneuronal neuroWbrillary tangles containing hyperphosphorylated microtubule-associated protein tau. Although the initiating molecular event(s) in AD are not known, oxidative stress produced by the generation of reactive oxygen species (ROS) appears to be a fundamental process contributing to the neuropathophysiology [10] . Whether oxidative stress has a role in the cause or aVect in AD has been debated for many years, but recent research has suggested that it occurs prior to the onset of symptoms [35] . The histopathological evidence for oxidative stress in AD includes lipid, protein and DNA oxidation. There is evidence to suggest that oxidative stress is generated peripherally [26] with the brain being particularly susceptible, but there is also a body of evidence to suggest that amyloid peptide (A 42) may be linked to lipid peroxidation [5, 6] , which may then be linked to the phosphorylation of tau [24] . Two reactive products of A 42-induced lipid peroxidation are the production of four hydroxynonenal and acrolein [5] , which have been shown to disrupt membrane asymmetry [7] and may be involved in the conformational changes to tau, promoting the formation of neuroWbrillary tangles [24] .
Oxidative damage occurs as part of the aging process, but it occurs at a much greater rate in most neurodegenerative diseases [3] . The hallmark of protein oxidation is the generation of protein carbonyls, which are markedly elevated in AD [3, 16] . There is overwhelming evidence to implicate oxidative stress in the pathogenesis of AD, and this is most likely an early event in the disease process. Less is known however of how the brain responds to oxidative insults. There are a number of cellular antioxidant defenses whose primary role is to convert the ROS into unreactive compounds. These defense mechanisms include superoxide dismutase, which works together with selenium-dependent glutathione peroxidase, catalase and more recently the peroxiredoxin family. These enzymes transform the superoxide radical to hydrogen peroxide , which in turn is converted to water. The distribution and changes in expression of the antioxidant enzymes have not been well studied as the other aspects of the disease process.
Cellular selenium-dependant glutathione peroxidase (GPx-1) has long been regarded as the major cellular antioxidant enzyme, but there are conXicting reports regarding the changes in activities of this enzyme in AD. Early reports suggest that there is no change in GPx-1 activities in AD brains [15, 20] , while other researchers suggest that there is a decrease in GPx-1 activity [8, 27, 32] . There are no reports indicating compensatory increase in GPx-1 activity; however, cell models overexpressing GPx-1 are more resistant to A -mediated toxicity, suggesting that increased levels of GPx-1 is protective [2] .
There is considerable evidence to implicate A toxicity and the generation of ROS and in particular hydrogen peroxide as key steps in contributing to the neurotoxicity in AD. We have previously reported that peroxiredoxin 6, also termed 1 Cys-peroxiredoxin or nonselenium glutathione peroxidase, is upregulated in Parkinson's disease (PD) [30] . This enzyme has no amino acid homology to any known sequence of the glutathione peroxidase enzymes and has both antioxidant and phospholipase A2 activity and can reduce hydroxyperoxides [9] . Given that the brain is particularly vulnerable to oxidative damage due to its high energy and oxygen requirements, high levels of transition metals and peroxidizable fatty acids suggests that peroxiredoxin 6 could play a key antioxidant role in neuroprotection.
There are six members of the peroxiredoxin family at this stage with peroxiredoxins 1-5 being the 2-Cys members while peroxiredoxin 6 is the sole 1-Cys member [36] . This enzyme is bifunctional with 80% of its function as a peroxidase and the remainder as a phospholipase A2. Peroxiredoxin 6 has not speciWcally been examined in brain tissue of AD patients, and the aims of this study are to examine the molecular forms, cellular distribution and association with AD pathology. This study focused on the cingulate, amygdala, hippocampus and cortical regions in six AD and six control brains. Brains were removed at autopsy from clinically diagnosed AD cases and conWrmed pathologically postmortem. The control cases were obtained from people who died of unrelated causes without diagnosed neurological pathology that was conWrmed postmortem. The brains were bisected and one half snap-frozen at ¡80°C and the other immersion Wxed in buVered formaldehyde. Tissue blocks were processed and embedded in paraYn and 8 m sections were cut and mounted onto gelatin-coated slides. Table 1 provides a list of the brain regions examined and the case details.
Materials and methods

Antibodies
Primary antibodies
Brain homogenate
Frozen tissue from midfrontal cortex of three AD brains and three control cases were homogenized in 50 mM Tris, 5 mM EDTA, 0.1% sodium azide, 1 l/ml pepstatin and leupeptin and 0.3 mM of phenylmethylsulfonyl Xuoride. Five milliliters of homogenization buVer was used per gram of brain tissue and homogenized using six passes of a motorized Wheaton TeXon pestle tissue grinder. Homogenates were centrifuged (500£g) for 10 min to remove particulate matter and snap-frozen at ¡80°C. Table 2 provides the details of these cases.
Sample preparation
Aliquots (100 l) of Alzheimer's and control brain homogenates underwent a 2D clean up as per the Amersham Biosciences protocol. The samples were then resolubilized in 300 l of TUC pH 4-7 buVer containing 7 M urea, 2 M thiourea, 4% CHAPS, 0.5% dithiothreitol, 0.5% IPG buVer pH 4-7. Samples were then assayed for total protein content. Prior to rehydration of the immobilized pH gradient strips, trace amounts of bromophenol blue was added to samples. Table 2 provides a list of cases used in the 2D electrophoresis.
2D polyacrylamide gel electrophoresis (PAGE)
Isoelectric focusing
Isoelectric focusing was performed on 13 cm immobilized pH gradient strips (pH 4-7NL, Amersham Pharmacia) using an IPGphor (Amersham Pharmacia) isoelectric focusing unit. Samples were applied in gel rehydration (50 V, overnight) using 7 M urea, 2 M thiourea, 4% CHAPS, 0.5% dithiothreitol, 0.5% pharmalyte pH 4-7 with a trace of bromophenol blue as the re-swell buVer with a total loading volume of 280 l including sample. Stained gels received a 400 g protein load and Western blotting gels received a 200 g load. IEF was performed for »60 kV h (500 V 30 min, 1,000 V 30 min, 1,000-8,000 V 30 min, 8,000 V 5-7 h, 1,000 V hold to end). 
SDS PAGE
SDS PAGE was performed using 12.5% acrylamide gels. Immobilized pH gradient strips were incubated in SDS equilibration buVer containing 1% w/v dithiothreitol for 15 min followed by SDS equilibration buVer containing 4% w/v iodoacetamide for 15 min. Strips were then placed above the second dimension gels and overlaid with 1% low melting point agarose in Tris glycine gel running buVer. Electrophoresis was performed at 350 V for 2.5-3 h at 10°C. Protein gels were visualized using SYPRO ruby Xuorescent stain (incubated for 2 h) and scanned using a Typhoon 9400 Variable Mode Imager (Amersham Biosciences).
Western blotting Separated proteins were transferred onto low Xuorescence PVDF membrane by semi-dry electroblotting at 0.8 mA/ cm 2 for 2 h. After blocking, the membranes were incubated in aYnity-puriWed rabbit antiperoxiredoxin 6 antibodies (1/ 2,000) overnight at 4°C followed by goat antirabbit alkaline phosphatase antibodies (1/10,000) (Sigma) for 1 h and visualized using ECF substrate and a Typhoon 9400 Variable Mode Imager.
Immunohistochemistry
Localization of peroxiredoxin 6
Immunohistochemical staining of AD and control tissue was carried out as previously described [30] . The cellular distribution of peroxiredoxin 6 was compared with the staining obtained with antibodies to speciWc cellular markers. Antibodies to GFAP (astrocytes), HLA (MHC2) (microglia), MBP (oligodendrocytes) and HuC/HuD (neurons) were used to map the distribution of peroxiredoxin 6.
Colocalization of peroxiredoxin 6, A and Tau
Brain sections were incubated with rabbit antiperoxiredoxin 6, mouse anti A peptide and goat anti tau antibodies overnight and detected with secondary antibodies conjugated to Xuorescent Xuorophores Cy5, Alexa 488 and Cy3, respectively. Sections were examined using a Bio-Rad Confocal laser scanning microscope and Bio-Rad software package, as previously described [30] .
Cell counting
Cell counting was carried out blind on masked sections, and peroxiredoxin 6 positive astrocytes were counted at 20£ magniWcation with a graticule eye piece (0.0625 mm 2 ) using an Olympus HO-2 microscope on brain tissue from six AD and six control cases. In each case, Wve regions were randomly selected to give a uniform representation of the white and gray matter in the cingulate, hippocampus, amygdala and midfrontal cortex. The number of positive cells from each of the Wve areas was averaged and divided by the area of the graticule eyepiece and expressed as cells/mm 2 . The data was then analyzed using a one-way ANOVA that examined the interactions listed in Table 3 . The signiWcance was determined at 0.01 level of probability. 
Results
Molecular forms of peroxiredoxin 6 in human brain
We have previously shown that this antibody is speciWc for a 26 kDa monomer in rat lung and human brain, and the Nterminal sequence is identical to peroxiredoxin 6 [30, 31] . Two-dimensional PAGE and Western blotting of AD and control brain homogenates indicated that this protein exists as three major and Wve minor forms as shown in Fig. 1a-d .
Although the loadings were consistent, the Wve minor forms could not be detected on all gels. For comparison, the spots were labeled 1-8 (Fig. 2) . The respective pIs of the eight forms are 5.3, 5.4, 5.6, 5.75, 5.85, 5.9, 5.95 and 6.1. The three major forms were 3, 6 and 7 and the average pIs of these were 5.59, 5.88 and 5.96 for AD tissue and 5.59, 5.80 and 5.86 for control tissue. These major forms were consistent in all homogenates. The intensity of the three major forms was analyzed using the Typhoon imager and the intensity of spots 6 and 7 was Fig. 1 a, 
The box indicates the location of the molecular forms of peroxiredoxin 6. Some spots are shown on the blots to indicate the range of peroxiredoxin 6 pIs reversed in the AD and control homogenates (Fig. 2) . Minor forms 1 and 2 were present in AD homogenates but absent in the control tissue, while minor form 8 was present in control tissue but absent in AD tissue (Fig. 2) .
Cellular distribution of peroxiredoxin 6 in control and AD brain tissue Using immunohistochemical markers for speciWc human brain cell types, we have shown that peroxiredoxin 6 is abundant in reactive astrocytes (Fig. 3a-c) in AD tissue and present in very low levels in neurons (Fig. 3j-l) . We were not able to detect peroxiredoxin 6 in either microglia ( Fig. 3d-f) or oligodendrocytes (Fig. 3g-i) .
There was a marked contrast between the staining of control and reactive astrocytes in AD. Reactive astrocytes in AD were hypertrophied with abundant staining of peroxiredoxin 6, while in control astrocytes the staining was conWned to a "halo" around the nucleus (Fig. 4) . The increased staining of peroxiredoxin 6 was seen in all regions examined and in both gray and white matter, but the staining was not evenly distributed and some regions on the same section were heavily labeled but adjacent regions showed little staining (Fig. 5) . 
Cell counting
In AD and control tissue, peroxiredoxin 6 was colocalized with GFAP, indicating that the upregulation is occurring in astrocytes, which is similar to what was found in PD and dementia with Lewy bodies [30] . Cell counting was conducted on midfrontal cortex, cingulate, amygdala and hippocampus brain regions and in gray and white matter to determine if speciWc areas or matter type were speciWcally aVected. These are summarized in Fig. 6 . A one-way ANOVA was performed comparing the cell counts between AD and control tissue in diVerent regions by tissue and matter type. The results of the interactions examined are shown in Table 3 .
Colocalization of peroxiredoxin 6 and AD pathology
The major deWning pathology in AD is the presence of extracellular plaques and intracellular hyperphosphorylated tau in the form of tangles. Plaques are present in brain tissue at diVerent stages of development, ranging from diVuse plaques to Wbrillar and neuritic plaques. It is generally considered that diVuse plaques do not contain tau, but neuritic plaques contain both A and tau. Colocalization of peroxiredoxin 6 and the A peptide, a major component of plaques, and tau was carried out to determine if peroxiredoxin 6 positive astrocytes were associated with AD pathology. 
Tau pathology
Tau deposits in the form of neuroWbrillary tangles were observed in many neurons and neurites, and were often surrounded by peroxiredoxin 6 astrocytes, which made multiple contacts (Fig. 7a-c) . Although astrocytes made many contacts with neurons, most neurons had very low levels of peroxiredoxin 6 and it did not appear to be upregulated or to be colocalized with tau in AD.
Plaques
DiVuse plaques contained strongly stained aggregations of A peptide. Peroxiredoxin 6 staining was conWned to astrocytes and their projections that were in close proximity to plaques (Fig. 7d-h ). Some astrocytes were observed within plaques, but generally the astrocyte cell bodies were on the periphery with their processes projecting into the plaques. Some plaques contained the beginnings of a dense core of amyloid and took on a "wagon wheel" appearance (Fig. 7i, j) . DiVuse plaques and those with A beginning to aggregate appeared to elicit a stronger peroxiredoxin 6 astrocytic response than those with a dense core of A .
Peroxiredoxin 6 staining of blood vessels
In many regions of the AD brain, there appeared to be strong peroxiredoxin 6 staining in the walls of many blood vessels, which could be seen to have multiple contacts with strongly staining activated astrocytes (Fig. 7k) .
Discussion
Peroxiredoxin 6, also known as 1-Cys peroxiredoxin or non-selenium glutathione peroxidase, is a human brain antioxidant enzyme that is abundant in activated astrocytes and present in low levels in neurons. On exposure to hydrogen peroxide, the N-terminal peroxiredoxin 6 corresponding to Cys 47 is readily oxidized, but as yet its redox partner has not been identiWed. Glutathione, lipoic acid and cyclophilin have all been implicated [13, 23, 29] . In addition to its peroxidase activity, peroxiredoxin 6 also has phospholipase A2 activity that might be signiWcant in the brain, which has a high lipid content [9] . Peroxiredoxin 6 staining of astrocytes is markedly elevated in many brain regions in PD and dementia with Lewy bodies [30] . We now show that it is upregulated in the astrocytes in AD and describe for the Wrst time the range of molecular forms of peroxiredoxin 6 in human brain in both control and AD tissue.
Three major variants and Wve minor forms were identiWed with pIs ranging from 5.3 to 6.1. There were three major diVerences in the peroxiredoxin 6 variants between control and AD tissue. The AD tissue had the two more acidic forms 1 and 2 that were not present in control tissue; the intensity of the major forms 6 and 7 were reversed between AD and control tissue and minor form 8 was absent in AD tissue. We can only speculate on the signiWcance of these Wndings at this stage, but diVerent forms may have diVerent aYnities for diVerent substrates that might be more abundant under various pathological conditions or the more acidic forms are the result of oxidation [11] . At this stage, we cannot determine whether these diVerences are true isoforms or post-translational modiWcations of the same protein, but would suspect the latter. These Wndings are in agreement with two previous proteomic studies in an AD mouse model and in human brain AD tissue, which reported elevated levels of peroxiredoxin 6 [33, 34] . A more recent study using PC12-resistant and PC12 cells treated with A also reported increased levels of peroxiredoxin 6 [11] . A -treated cells contained an extra acidic form, which was suggested to be the result of oxidation of the catalytic cysteine to a sulfenic, sulWnic or sulfonic derivative. We found two minor acidic forms in AD tissue, which is also consistent with this report.
Tissue selection is also a variable that needs to be considered. While the AD tissue had all the hallmarks of AD pathology and was easy to deWne, age-matched control tissues are somewhat more variable. All the control tissue was from people without clinically deWned AD, but most brains in this age group usually contain some neurodegenerative pathology. The age span of the two groups was similar, 59-84 years for the AD group and 61-86 years for the con- trol group, but the mean age for the control group was 7 years older. We feel conWdent that, although some control tissue may have had some elements of subclinical AD pathology, the reduced level of astrocyte activation and the clear diVerences in the cell counting would indicate that all the control tissues were not experiencing high levels of oxidative stress as compared to the AD tissue.
Previously, we had shown that peroxiredoxin 6 was abundant in astrocytes in PD and dementia with Lewy body tissue [30] . We have now used cellular markers to other brain cell types to show that in addition to astrocytes there is a low level in the cytoplasm of most neurons. Unlike astrocytes, neurons do not appear to have increased peroxiredoxin 6 staining in AD tissue. We could not detect any peroxiredoxin 6 staining in microglia or oligodendrocytes.
Cell counting of peroxiredoxin 6 positive astrocytes indicated that there was a marked increase in both the gray and white matter in AD tissue compared with control tissue. Gray matter had more peroxiredoxin 6 positive astrocytes than white matter in both AD and control tissue, and this diVerence was more pronounced in AD tissue with F values of 89.0 and 14.5, respectively. Considering that the major pathology (plaques and tangles) is located in the gray matter, it would be expected that oxidative stress is staining of astrocytes and astrocyte foot processes in the walls of blood vessels in the midfrontal cortex in Alzheimer's disease (£400). Arrows indicate peroxiredoxin 6 positive astrocytic processes more pronounced in this area. Cell counting indicated that the peroxiredoxin 6 positive astrocyte numbers were elevated in all regions examined, suggesting that the insult activating astrocytes is wide spread and not conWned to any speciWc region in either the gray or white matter. Indeed, extracellular plaques were observed in all regions examined in AD tissue. Although all regions examined showed astrocyte activation, this was not uniformly distributed through all areas, with some areas showing extensive astrocyte activation while adjacent areas were similar to controls.
There are two deWning pathologies in AD. These are the presence of extracellular plaques comprising abundant deposits of A peptides, which later aggregate to form amyloid [25] and intracellular hyperphosphorylated tau aggregations in the form of paired helical Wlaments, which are termed tangles [14, 22] . The two well-described forms of plaques have been termed diVuse plaques and neuritic or senile plaques [12, 18] , although other intermediate forms such as Wbrillar plaques have been described [12] . DiVuse plaques are spherical structures of less dense A deposits and are considered an early stage of plaque formation. In diVuse plaques, aggregations of A exists as nonamyloid deposits, but as the plaque progresses, the A and other protein aggregations change from the normal conformation into a -sheet structure, termed amyloid, and take up speciWc dyes like Congo red and thioXavin [4] . These plaques do not generally contain tau; however, in many confocal images, diVuse plaques contain focal points of tau, which are probably enlarged neurites. Neuritic or senile plaques contain a dense core of amyloid enriched with A peptide with a corona of less dense amyloid. The diVuse plaques appeared to elicit a stronger astrocytic response based on the level of peroxiredoxin 6 staining than the neuritic plaques. Our images suggest that once the A forms amyloid and condenses, it is less stimulating toward astrocytes and perhaps the formation of amyloid is a protective mechanism to inactivate the toxicity of soluble A . These observations are consistent with the Wndings of KawaguchiNiida et al., who reported that the highly reactive carbonyl crotonaldehyde generated during lipid peroxidation is localized to reactive astrocytes, microglia and diVuse plaques but undetectable in amyloid cores [19] .
Although the activation of astrocytes and upregulation of peroxiredoxin 6 would be considered a protective response, in cell culture, soluble A has been shown to stimulate nitric oxide synthetase and the production of nitric oxide, which is very damaging to neurons [17] . This response is further upregulated by other inXammatory cytokines such as interleukin 1 and tumour necrosis factor-, which are reported to be released from astrocytes [1] . At this stage, we are not sure of the net beneWt to neural tissue of activated astrocytes with elevated levels of peroxiredoxin 6, concomitant with the increased production of nitric oxide.
NeuroWbrillary tangles comprising hyperphosphorylated tau were observed in many regions in AD tissue. Two antibodies were used to localize tau, a monoclonal antibody (Novacastra) and one speciWc for paired helical Wlaments (Santa Cruz) and both produced a similar staining pattern. Neurons containing tau were not surrounded by activated astrocytes as were the diVuse plaques and to a lesser extent the neuritic plaques, suggesting that these cells are not secreting toxic or activating products that are stimulating to astrocytes. In PD, Lewy bodies contained a dense core of peroxiredoxin 6 staining suggesting that it was trying to detoxify oxidative stress produced by Lewy bodies, but we did not observe any interaction between tau and peroxiredoxin 6 in AD tissue. Although there is considerable evidence to implicate oxidative stress in the hyperphosphorylation of tau, this does not appear to upregulate peroxiredoxin 6 in tau positive neurons.
In some regions, the walls of blood vessels exhibited strong peroxiredoxin 6 staining, which also elicited a strong astrocytic response in surrounding astrocytes. These activated astrocytes had many processes in contact with the endothelial cells. Although vascular amyloid deposits were seen in some sections and is a key feature of AD [28] , the upregulation of peroxiredoxin 6 appeared to occur in regions without distinct A staining. A has been shown to induce vascular vasoconstriction in rat skin, which can be reversed by superoxide dismutase and catalase, indicating that A is capable of generating ROS within blood vessels [21] . The blood brain barrier consists of the capillary endothelial cells, and the foot processes of the astrocytes and the fused basal lamina of both cells. The peroxiredoxin 6 staining within the capillaries appears to be in the foot processes of the astrocytes. Whether this increased staining is due to ROS generated from within neural tissue or reXects a more systemic pathology derived from the circulation is unclear.
In conclusion, we have shown for the Wrst time the range of peroxiredoxin 6 variants, which are either isoforms or post-translational modiWcations in human brain tissue. We have also shown that peroxiredoxin 6 is primarily an astrocytic enzyme with very low levels in neurons and is not detectable in microglia or oligodendrocytes. This enzyme is markedly elevated in astrocytes in both white and gray matter in AD. Strongly staining peroxiredoxin 6 astrocytes appear to be involved in the detoxiWcation of diVuse plaques and to a lesser extent in neuritic plaques, but is not associated with tau aggregations within neurons. From this work and previous work on PD and dementia with Lewy bodies, we suggest that peroxiredoxin 6 is a major antioxidant enzyme in human neural tissue.
